Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0020538 (hypertension)
 170,190 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The multiple endocrine neoplasia syndromes are an association of tumours of 2 or more endocrine glands. Multiple endocrine neoplasia type 2b (MEN 2b) patients develop medullary thyroid carcinoma and pheochromocytomas as well as unique physical characteristics. Most commonly, MEN2b is inherited with an autosomal dominant pattern although sporadic cases are not uncommon. If untreated the disease may be lethal. The facial, oral and ocular characteristics are reliable markers of the disease. These patients give a history most commonly of slipped capital femoral epiphysis, hypertension and life-long diarrhoea and/or constipation. MEN2b is most commonly characterised by nodules on the anterior aspect of the tongue, thickened lips with nodules, thickened upper eyelids, broadened nasal bridge, thickened corneal nerves and dilated, symmetrical, pedunculated nodules on the cheek mucosa. The patient described has most of these characteristics. Radiographic features of the jaws which have not been previously described are reported. These include a markedly enlarged and bifurcated inferior alveolar canal and shortened roots of the lower incisor teeth. Due to the lethality of the disease, patients who present with the above physical characteristics must be further investigated to exclude MEN2b.
 ...
PMID:Multiple endocrine neoplasia syndrome--type 2b. Case report and review. 135 Oct 93

Blood flow in the hind-limb bones of 8 immature labrador dogs with unilateral knee joint tamponade at 75 percent of the mean arterial pressure was measured with 15-microns and 50-microns microspheres to determine whether or not arteriovenous shunting occurs in bone with venous congestion caused by increased outflow resistance. The intraosseous pressure was 43 percent of the mean arterial pressure in the experimental distal femoral epiphysis versus 14 percent in the control knee (P less than 0.001). No pressure changes were found in the distal femoral metaphysis. Regional blood flow with 15-microns microspheres decreased centrally in the distal femoral epiphysis and increased centrally in the proximal tibial epiphysis. Metaphyseal blood flow was largely unchanged. A net shift in the preferred embolization site of 50-microns microspheres relative to that of 15-microns microspheres from central to peripheral regions occurred within both juxtaarticular epiphyses, indicating arteriolar vasodilation, but the relation between the uptake of the two microsphere sizes was unchanged when the epiphyses and other bony flow compartments were viewed in toto. The result speaks against the hypothesis of arteriovenous shunting in intraosseous hypertension.
 ...
PMID:Arteriovenous shunting is not associated with venous congestion in bone. Knee tamponade studied with 15-microns and 50-microns microspheres in immature dogs. 204 71

A new ultrasonic method based on X-ray concepts for depicting prenatally developed centers in the tarsal bones, calcaneus and talus, as well as and especially in the epiphysis centers of the fetal knee joint is described. Investigations of average collectives show that the center in the calcaneus becomes visible during the 24th week of pregnancy, on the average, whereas the center in the talus becomes visible during the 26th week after begin of amenorrhea. The growth charts of both these tarsal centers demonstrate almost linear growth until parturition, the very slight increase per week, however, limits the possibilities for their use in determining the period of gestation. The epiphysis center in the distal femur becomes visible by ultrasonic methods during the 32nd week of pregnancy, on the average, the center in the proximal tibia appears later, during the 37th week after amenorrhea begins. Both epiphysis centers show an almost linear increase in size from the time they first appear; the center in the femur, however, has a growth chart that shows levelling off after the 38th week of pregnancy. The differences between X-ray and ultrasonic representation, which become evident upon comparing growth charts as well as in a separate and direct comparison are shown to be due, through the results of a parallel histological study, to an increase in density of the cartilage matrix prior to ossification. Of the fetal factors which were investigated only the weight and length of the child show a slight, and for practical purposes negligable influence on the size of the epiphysis centers, whereby only the results showing that the femur centers tend to be larger when the child is heavier and longer appear significant. Neither sex nor maternal factors influence the size of the visible epiphysis centers in any way. A slight modification in the case of diabetics and pregnancy induced hypertension patients seems to most likely be due to the macrosomal and retarded children occurring in these groups. None of the factors investigated effect a significant difference in the ultrasonic development or time of appearance of the epiphysis centers. In view of the fact that growth charts show levelling off and of the wider biological scattering range of all parameters currently used to determine the duration of gestation during the last trimenon, making use of this new ultrasonic method with its double advantage - the first appearance of the centers during the last quarter of pregnancy as well as the following near-linear increase in size - seems to suggest itself.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:[Sonographic detection of fetal epiphyseal centers--an additional parameter for determining delivery date]. 389 Mar 74

An isorenin is synthetized in the pineal gland cells. For the synthesis of angiotensin I and II a supply of alpha2 globulin renin substrate is necessary. The amount of isorenin as well as of angiotensin I and II in the pineal gland depends on the circadian rhythm, the sleep-wakefulness cycle, osmotic stimuli, stimulation of the sympathetic postganglionar fibres which innervate the pineal gland and it is increased in some diseases, as hereditary diabetes insipidus and spontaneous hypertension in rat. Pineal angiotensin is released both into the blood and into the cerebrospinal fluid (CSF). The major sites of action are the circumventricular organs, the periventricular receptors of the anterior hypothalamus and the epiphysis cerebri itself. Beside its participation in the regulation of arterial pressure and of the hydroelectrolytic metabolism through its direct effects on the brain, pineal angiotensin also participates in the pool of circulating angiotensin and it may represent Farrell's pineal glomerulotropic factor.
 ...
PMID:Is angiotensin a new pineal hormone? 702 26

The present study was performed in 9 mongrel puppies, 8-10 weeks old. Under anaesthesia simultaneous pressure registrations were taken from the distal femoral metaphysis, the distal femoral epiphysis, the proximal tibial epiphysis together with the arterial pressure. An intra-articular pressure increase resulted in a significant increase in the intraosseous pressure in the distal femoral epiphysis, while the pressures in the femoral metaphysis and tibial epiphysis remained unchanged. During maximal flexion of the empty joint a significant increase in femoral epiphyseal pressure was observed, while maximal extension resulted in a significant increase in tibial epiphyseal pressure. The presence of a moderate intra-articular effusion augmented these findings. By selective ligation of the venous drainage from the juxta-articular bones in the popliteal fossa and on the femur, different levels of epiphyseal hypertension could be produced. These pressure increases never reached the level of the arterial pressure. Thus they revealed only a partial impairment of the vascular circulation in the juxta-articular bones.
 ...
PMID:Intraosseous pressures in the knee in relation to simulated joint effusion, joint position, and venous obstruction. An experimental study in growing dogs. 732 84

The National Cooperative Growth Study has monitored the safety of recombinant human GH (rhGH) since 1985. Data have been collected from more than 19,000 children representing over 47,000 patient-years of rhGH treatment. Children receiving GH for renal disease were more likely to develop problems such as intracranial hypertension than those with GH deficiency (P < 0.01). Children with idiopathic short stature were less likely to develop slipped capital femoral epiphysis than those with GH deficiency or Turner's syndrome (P < 0.01). There was no evidence of an increased recurrence of leukemia or central nervous system tumors. There were 3 new cases of leukemia in children without known risk factors for developing leukemia and 5 cases in children with known risk factors. Growth deceleration associated with high affinity, high capacity antibodies to GH was found in only 2 of 5039 subjects tested (0.04%). Major adverse events in association with rhGH treatment have been rare, and preexisting medical conditions such as renal insufficiency may affect their frequency.
 ...
PMID:Safety of recombinant deoxyribonucleic acid-derived growth hormone: The National Cooperative Growth Study experience. 862 20

The growth hormone (GH) cascade and the remarkable advances over the past four decades in our knowledge of its components are considered. It is now over 40 years since human pituitary GH (pit-hGH) was purified and the first GH-deficient patient, a 17-year-old male, was successfully treated with pit-hGH. However, the shortage of pit-hGH limited its use and the dose, the biopotency of preparations varied, strict criteria of GH deficiency (GHD) were used for patient selection including peak plasma immunoreactive GH levels after provocative stimuli of <3.5-5 ng/ml, treatment was not infrequently interrupted, the mean age for initiating treatment was often late in childhood (12-13 years) and the growth deficiency severe (height -4 to -6 SDS), and finally pit-hGH therapy was often discontinued when girls attained a height of 5' and boys 5'5". Nonetheless, the effects of pit-hGH were dramatic; the final height SDS increased in isolated GHD to about -2 SDS in boys and -2.5 to -3.0 SDS in girls, and in multiple pituitary hormone deficiencies to between -1 and -2 SDS. Between 1962 and 1985 when the Creutzfeldt-Jakob disease crisis struck, the number of GH-deficient patients treated with pit-hGH increased from about 150 to over 3,000. The advent of biosynthetic GH (rhGH) and its availability to treat large numbers of idiopathic GH-deficient children (the minimum prevalence rate of which in the USA and UK is between 1 in 3,400 and 4,000) dramatically changed this picture in 1985. It is estimated that more than 60,000 patients have been or are now on treatment. With rhGH treatment the attained mean adult height SDS is now about -1.0, and in our experience with the treatment of patients under 4 years of age, final height may exceed the target height. It is now recognized that (a) the replacement dose of rhGH ranges from 0.175 to 0.35 mg/kg/week and should be individualized; (b) dividing this dose into 6 or 7 daily subcutaneous injections is more effective than giving the same total dose in three weekly portions, and (c) final height correlates significantly with pretreatment chronologic age, height SDS and predicted adult height, duration of therapy, birth length, in some studies height SDS and age at start of puberty, weight, and serum GHBP (an indicator of GH receptor mass). Early recognition of GHD is essential for an optimal height outcome. rhGH treatment should not be delayed in children with documented GHD; the greater the height deficit, the lower the probability that target height will be reached. GHD needs to be detected earlier in children with organic hypopituitarism whether due to a developmental defect, neoplasm, radiation, head trauma, or a CNS infection. Early rhGH therapy in neonatal hypopituitarism has resulted in excellent growth responses. As the height prognosis in isolated GHD is not as good (especially in girls) as in GHD associated with gonadotropin deficiency, the use of LHRH agonists to delay puberty or potent aromatase inhibitors to delay skeletal maturation should be considered in selected patients with isolated GHD. When the growth response to rhGH is less than predicted, one must consider: (a) poor compliance; (b) improper preparation of rhGH for administration or faulty injection techniques; (c) the timing of administration; (d) the dose of glucocorticoid in the ACTH-deficient patient; (e) occult hypothyroidism; (f) inadequate nutrition; (g) a chronic illness; (h) neutralizing antibodies to rhGH, and (i) the wrong diagnosis. The major cause of mortality (unrelated to Creutzfeldt-Jakob disease or a CNS neoplasm) is adrenal crisis and hypoglycemia in children with both GH and ACTH deficiency. Major adverse effects of rhGH treatment in children are uncommon and include idiopathic intracranial hypertension, slipped capital femoral epiphysis, and acute pancreatitis. The rhGH is not an added risk for leukemia in the US and Europe in the absence of coexisting risk factors, nor is there a higher risk of recurrence of b
 ...
PMID:The growth hormone cascade: progress and long-term results of growth hormone treatment in growth hormone deficiency. 973 Jun 72

The spontaneously hypertensive rat (SHR) is a widely used animal model for the study of hypertension. It also exhibits an osteonecrosis of the femoral epiphysis that resembles the clinical features of Perthes' disease in humans. In this rat model, occlusion of the epiphyseal vessels occurs as a result of a breakdown of the mechanically vulnerable epiphysis. The postnatal development of the epiphysis recapitulates the serial events of the endochondral ossification (i.e., cartilage formation), chondrocyte hypertrophy, cartilage mineralization, vascularization, and introduction of osteoblasts that form the secondary ossification center within the epiphysis. In the present study, a detailed radiographic and histological analysis demonstrates that the osteonecrosis is preceded by a disturbance of the cartilage mineralization and a disturbance of the ossification, despite a normal hypertrophy of the epiphyseal cartilage. These observations suggest that abnormal development of the femoral epiphysis occurs much earlier than manifestation of the osteonecrosis. They lead us to a hypothesis that yet-unclarified transitional events between the cartilage hypertrophy and the cartilage mineralization may be affected in SHRs. Type X collagen is a developmentally regulated matrix molecule that is implicated in the mineralization of the hypertrophied chondrocytes. We show that the expression of type X collagen during epiphyseal ossification is delayed in SHRs (vs. normal controls), suggesting disturbed growth and/or differentiation of the epiphyseal chondrocytes. Postnatal growth and differentiation of the chondrocytes at least partly depend on insulin-like growth factor-I (IGF-I), which is produced by the chondrocytes in response to the pituitary growth hormone and stimulates cartilage growth in situ. The present study demonstrates an altered IGF-I expression during early postnatal life in SHRs and suggests that the altered IGF-I expression as well as the following delay in upregulation of type X collagen may cause the mechanical vulnerability of the femoral epiphysis in SHRs.
 ...
PMID:Altered postnatal expression of insulin-like growth factor-I (IGF-I) and type X collagen preceding the Perthes' disease-like lesion of a rat model. 1064 20

We reviewed adverse event (AE) data in the National Cooperative Growth Study from start-up (1985) until January 1, 1999. Enrollment was 33,161. A total of 2,632 AE reports were received; 863 were serious events, with 156 deaths. The most common cause of death was recurrence of intracranial neoplasm. There were 20 reports of leukemia, and the standard morbidity ratio (SMR) was 0.73 (95% CI: 0.20-1.86) for the four cases without risk factors. There were 35 reports of extracranial nonleukemic malignancy, and the SMR was 0.44 (95% CI: 0.24-0.74) for the 14 cases without risk factors. The recurrence rate for all brain tumors present at baseline was 7.6%, and for craniopharyngiomas, 6.4%. There were 49 reports of intracranial hypertension (20 patients had papilledema), 68 reports of diabetes/hyperglycemia, 45 of slipped capital femoral epiphysis, 136 of scoliosis, and five of pancreatitis. There was no evidence of increased incidence of leukemia or extracranial nonleukemic malignancies among patients without prior risk factors. Intracranial hypertension does not necessarily occur early in growth hormone therapy. Other findings were consistent with past observations.
 ...
PMID:Growth hormone safety update from the National Cooperative Growth Study. 1108 59

The action of growth hormone (GH) via its receptor involves many organ systems and metabolic pathways. These diverse actions are reviewed in this paper in the context that they may represent unwanted side-effects of GH therapy for growth promotion. The monitoring of GH therapy in large multicentre international databases has demonstrated a low frequency of adverse events. Tumour recurrence or new malignancy are not increased. Headaches, especially in the first few months of therapy, require close evaluation as benign intracranial hypertension is found infrequently, especially in children with GH deficiency and chronic renal failure (CRF). Children at risk for slipped capital femoral epiphysis and scoliosis require close monitoring during therapy. Decreased insulin sensitivity that is dose-dependent is observed during GH therapy. Glucose homeostasis, however, is not affected, but a recent report of increased incidence of Type 2 diabetes mellitus in children undergoing GH therapy requires prospective surveillance.
 ...
PMID:Safety issues in children and adolescents during growth hormone therapy--a review. 1173 34


1 2 Next >>